# Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

> **NCT06783153** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Mansoura University** · enrollment: 80 (estimated)

## Conditions studied

- Radiotherapy Induced Diarrhea
- Acute Radiation Enteritis
- Prostate Cancer
- Cervical Adenocarcinoma
- Bladder (Urothelial, Transitional Cell) Cancer
- Rectal Adenocarcinoma
- Pelvic Radiotherapy
- Rifaximin

## Interventions

- **DRUG:** Rifaximin 550 MG
- **DRUG:** Standard Care Chemoradiation

## Key facts

- **NCT ID:** NCT06783153
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06783153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06783153, "Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06783153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*